Trial intelligence / Profile preview

Vorolanib Combined With Everolimus in Advanced Renal Carcinoma After Immunotherapy Failure

NCT06730672Phase 2

Key facts

Status: Recruiting
Start: Dec 2025
Primary completion: Dec 2027
Countries: 1
Sponsor: Sun Yat-sen University
Modality: Small Molecules

Drugs: vorolanib
Conditions: clear cell renal cell carcinoma (ccRCC)

Overview

Phase 2, open-label, single-arm trial of vorolanib in clear cell renal cell carcinoma (ccRCC), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 36 months. Started Dec 2025; status: recruiting.

Design

1 arm

Study design: Non-randomizedOpen-labelSingle group

Volonib combined with Everolimus Formation
Vorolanib 200mg once daily and Everolimus 5mg once daily

Who it enrols

Adult patients (18-75 years) with clear cell renal cell carcinoma who have failed prior treatment with an immune checkpoint inhibitor and no more than 2 targeted drugs, with ECOG <= 1 and adequate organ function.

Endpoints

Primary

Progression-Free Survival36 months

Secondary

Overall Survival36 months
Objective Response Rate36 months
Disease Control Rate36 months
Duration of Response36 months
Dynamic changes in ctDNA levels and alterations in the ctDNA mutation profile36 months

Beyond the preview

Go deeper on NCT06730672.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT06730672.